2021
DOI: 10.1016/j.jinf.2020.09.031
|View full text |Cite
|
Sign up to set email alerts
|

Sex differences in mortality in the intensive care unit patients with severe COVID-19

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
10
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(10 citation statements)
references
References 6 publications
0
10
0
Order By: Relevance
“…Looking at mortality according to gender, it seems the effect of fluvoxamine was more significant among female COVID‐19 ICU patients. Gender differences in mortality in ICU COVID‐19 patients have been described before, with significantly lower mortality rates among women 28 . Also, gender‐specific differences in fluvoxamine pharmacokinetics have been described in the published literature, 29 as well as gender differences in CYP2D6 30 and CYP1A2 31 enzyme activity.…”
Section: Discussionmentioning
confidence: 77%
See 1 more Smart Citation
“…Looking at mortality according to gender, it seems the effect of fluvoxamine was more significant among female COVID‐19 ICU patients. Gender differences in mortality in ICU COVID‐19 patients have been described before, with significantly lower mortality rates among women 28 . Also, gender‐specific differences in fluvoxamine pharmacokinetics have been described in the published literature, 29 as well as gender differences in CYP2D6 30 and CYP1A2 31 enzyme activity.…”
Section: Discussionmentioning
confidence: 77%
“…Gender differences in mortality in ICU COVID‐19 patients have been described before, with significantly lower mortality rates among women. 28 Also, gender‐specific differences in fluvoxamine pharmacokinetics have been described in the published literature, 29 as well as gender differences in CYP2D6 30 and CYP1A2 31 enzyme activity. Whether the same gender‐specific differences which impact COVID‐19 mortality also play a role in the response to fluvoxamine treatment, or whether biological sex‐specific differences in cytochrome P450 enzymes CYP2D6 and/or CYP1A2 could be responsible for improved efficacy in female patients and consequently better outcomes remains to be investigated in additional studies.…”
Section: Discussionmentioning
confidence: 99%
“…Recently in this Journal, Sergey Moiseev et al reported that the mortality rate in intensive care unit patients with severe COVID-19 was higher in males older than 50 years old in contrast to females of similar age based on a nationwide cohort study [1] . The sex differences between mortality rates cannot be explained by comorbidities, given the increased occurrence of chronic illnesses in females that may worsen survival in COVID-19 patients.…”
mentioning
confidence: 99%
“…A null causal relationship was observed for TT or SHBG levels with COVID-19 outcomes in females and males. The relationships between gender difference, sex hormone difference and COVID-19 outcomes have been reported based on several observational studies [ 1 , 4 ] and various hypotheses have been postulated to explain the relationships, including a sex-dependent difference in immune responses, sex-related expression difference of angiotensin-converting enzyme 2 and transmembrane protease serine 2 [5] , [6] , [7] . Our study demonstrated a direct causal effect of BAT levels and COVID-19 hospitalization and severe disease in females based on MR analysis.…”
mentioning
confidence: 99%
“…In particular, several key genes have been reported from pathological pathway of both diseases, such as angiotensin-converting enzyme 2 (ACE2), A disintegrin and metalloproteinase domain 17 (ADAM17), transmembrane serine protease 2 (TMPRSS2), and melanoma adhesion molecule (CD146/MCAM). In addition, mortality caused by COVID-19 has a sex difference, with a worse rate in men [ 8 , 9 ]. Evidently, it has been known that sex difference exists in CKD.…”
Section: Introductionmentioning
confidence: 99%